A Post-Authorisation Safety Study Patient Registry of Patients With High-risk Neuroblastoma Being Treated With the Monoclonal Antibody Dinutuximab Beta
Latest Information Update: 15 Jun 2023
At a glance
- Drugs Dinutuximab beta (Primary) ; Antihistamines; Gabapentin; Interleukin-2; Non-opioid analgesics; Opioid analgesics; Pregabalin; Tretinoin
- Indications Neuroblastoma
- Focus Adverse reactions
- Sponsors EUSA Pharma
- 29 Sep 2020 Planned End Date changed from 15 Jan 2032 to 15 Jun 2032.
- 29 Sep 2020 Planned primary completion date changed from 30 Oct 2031 to 31 Mar 2032.
- 29 Sep 2020 Status changed from active, no longer recruiting to recruiting.